サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1513682

ペットアレルギー治療の世界市場：産業分析、規模、シェア、成長、動向、予測、2024～2031年

Pet Allergy Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

出版日
ページ情報
英文 156 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
ペットアレルギー治療の世界市場：産業分析、規模、シェア、成長、動向、予測、2024～2031年
出版日: 2024年07月10日
発行: Persistence Market Research
ページ情報: 英文 156 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

当レポートは、世界のペットアレルギー治療市場に関する包括的なレポートを発表しました。市場促進要因・動向・機会・課題などの主要な市場力学を詳細に分析し、市場展望に関する詳細な洞察を提供しています。

主な洞察

  • ペットアレルギー治療の市場規模（2024年）：26億7,120万米ドル
  • 予測市場金額（2031年）：39億3,076万米ドル
  • 世界市場成長率（CAGR 2024～2031年）：5.7%

ペットアレルギー治療市場 - 調査範囲

ペットアレルギーは、ペットとその飼い主の双方にとって、世界的に重大な健康問題です。ペットアレルギー治療市場には、猫や犬などのペットが引き起こすアレルギー反応を管理することを目的としたさまざまな治療オプションが含まれます。これらの治療には、薬物療法、免疫療法、アレルゲン回避戦略、新たな生物学的療法などが含まれます。同市場は、動物病院、病院、ペットケアセンター、在宅介護施設に対応しており、効果的なアレルギー管理ソリューションを求める飼い主からの需要の高まりに対応しています。

市場成長の促進要因：

世界のペットアレルギー治療市場は、ペット飼育の増加、ペットアレルギーに対する意識の高まり、獣医学の進歩など、いくつかの要因によって牽引されています。ペットの飼い主やペットの間でアレルギー疾患が蔓延していることから、効果的な治療オプションの必要性が高まっています。診断ツールや治療方法における技術革新は、診断精度と治療効果を向上させ、市場の成長をさらに促進します。さらに、ペット保険の適用範囲拡大やペットヘルスケアインフラへの投資も市場拡大に寄与しています。

市場抑制要因：

有望な成長が見込まれるもの、ペットアレルギー治療市場は、規制遵守、治療結果のばらつき、飼い主の処方治療遵守に関する課題に直面しています。動物用医薬品や生物製剤を管理する規制の枠組みは、メーカーやヘルスケアプロバイダーにコンプライアンス上の負担を課し、市場のダイナミクスや経営戦略に影響を与えています。さらに、一部の地域では先進治療のコストが高く、償還範囲が限られているため、特に新興国では市場浸透の妨げとなっています。

市場機会：

ペットアレルギー治療市場は、人口動態の動向、ペットの人間化の進展、ペットヘルスケア製品・サービスに対する消費者の嗜好の進化によって大きな成長機会がもたらされます。遠隔医療とデジタルヘルスソリューションの統合により、遠隔診察が容易になり、飼い主の獣医療へのアクセスが向上します。さらに、動物用製薬会社、ペットフードメーカー、アレルギー専門医の連携により、治療プロトコルとアレルゲン管理戦略の革新が促進されます。新たな市場機会を活用するには、研究開発への戦略的投資とともに、飼い主や獣医専門家を対象とした教育イニシアティブが不可欠です。

本レポートで扱う主な質問

  • ペットアレルギー治療市場の世界の成長を促進する要因は何か？
  • ペットの飼い主や獣医専門家の間でどのような治療法や診断ツールが支持を得ているか？
  • 技術の進歩はペットアレルギー治療市場の競合情勢をどのように変えているか？
  • ペットアレルギー治療市場に貢献している主要プレイヤーは誰で、市場のリーダーシップを維持するためにどのような戦略を採用しているのか？
  • 世界のペットアレルギー治療市場の新たな動向と将来展望は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/分類
  • 市場の定義/範囲/制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主な動向
  • 製品イノベーション/開発動向

第4章 付加価値の洞察

  • 製品採用分析
  • ブランド別製品 USP/機能分析
  • 国別の規制状況
  • 最近の製品承認/発売
  • 疾病疫学
  • ポーターの分析
  • PESTLE分析
  • バリューチェーン分析
  • アンメットニーズ

第5章 市場背景

  • マクロ経済要因
  • 予測要因 - 関連性と影響
  • 市場力学

第6章 世界市場の需要（金額または規模、100万米ドル）分析

  • 過去の市場金額（100万米ドル）分析、2019～2023年
  • 現在および将来の市場規模（100万米ドル）予測、2024～2031年
    • 前年比成長動向分析
    • 絶対的ドル機会分析
  • 収益機会シナリオ - 可能性が高い/保守的/楽観的

第7章 世界市場分析：薬剤クラス別

  • イントロダクション/主な調査結果
  • 過去の市場規模（100万米ドル）分析、薬剤クラス別、2019～2023年
  • 現在および将来の市場規模（100万米ドル）分析と、予測、薬剤クラス別、2024～2031年
    • 抗ヒスタミン薬
    • 副腎皮質ステロイド
    • 免疫療法
    • 抗生物質
  • 市場魅力分析：薬剤クラス別

第8章 世界市場分析：適応症別

  • イントロダクション/主な調査結果
  • 過去の市場規模（100万米ドル）分析、適応症別、2019～2023年
  • 現在および将来の市場規模（100万米ドル）分析と、予測、適応症別、2024～2031年
    • アレルギー性皮膚炎
    • 食物アレルギー
    • ノミダニ・アレルギー
    • 接触アレルギー
  • 市場魅力分析：適応症別

第9章 世界市場分析：ペットタイプ別

  • イントロダクション/主な調査結果
  • 過去の市場規模（100万米ドル）分析、ペットタイプ別、2019～2023年
  • 現在および将来の市場規模（100万米ドル）分析と、予測、ペットタイプ別、2024～2031年
    • 犬
    • 猫
    • げっ歯類・ウサギ
  • 市場魅力分析：ペットタイプ別

第10章 世界市場分析：投与経路別

  • イントロダクション/主な調査結果
  • 過去の市場規模（100万米ドル）分析、投与経路別、2019～2023年
  • 現在および将来の市場規模（100万米ドル）分析と、予測、投与経路別、2024～2031年
    • 経口剤
    • 注射剤
    • 局所
  • 市場魅力分析：投与経路別

第11章 世界市場分析：流通チャネル別

  • イントロダクション/主な調査結果
  • 過去の市場規模（100万米ドル）分析、流通チャネル別、2019～2023年
  • 現在および将来の市場規模（100万米ドル）分析と、予測、流通チャネル別、2024～2031年
    • 動物病院
    • 小売薬局
    • オンライン薬局
    • その他
  • 市場魅力分析：流通チャネル別

第12章 世界市場分析：地域別

  • イントロダクション/主な調査結果
  • 過去の市場規模（100万米ドル）分析、地域別、2019～2023年
  • 現在および将来の市場規模（100万米ドル）分析と、予測、地域別、2024～2031年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 南アジア
    • 東アジア
    • オセアニア
    • 中東・アフリカ
  • 市場魅力分析：地域別

第13章 北米市場分析

第14章 ラテンアメリカ市場分析

第15章 欧州市場分析

第16章 東アジア市場分析

第17章 南アジア市場分析

第18章 オセアニア市場分析

第19章 中東・アフリカ市場分析

第20章 市場構造分析

  • 市場分析：企業階層別
  • 主要企業の市場シェア分析（%）
  • 市場プレゼンス分析

第21章 競合分析

  • 競合ダッシュボード
  • 主要開発分析
  • 主要プレーヤーによるブランディングとプロモーション戦略
  • 競合の詳細
    • Zoetis Animal Healthcare
    • Merck and Co.Inc.（US）
    • Boehringer Ingelheim GmbH
    • Elanco Animal Health Incorporated
    • Bayer AG
    • Vetoquinol SA
    • Dechra Pharmaceuticals PLC
    • Virbac SA
    • IDEXX Laboratories, Inc.
    • Ceva Sante Animale
    • Kindred Biosciences, Inc.
    • Phirbo Animal Health
    • Norbrook Laboratories Limited
    • Vetiquinol SA
    • Neogen Corporation
    • PetIQ, Inc.
    • Huvepharma AD
    • Chanelle Pharma Group Limited
    • Kepro
    • Biogenesis Bago

第22章 使用される仮定と頭字語

第23章 調査手法

目次
Product Code: PMRREP28603

Persistence Market Research has recently released a comprehensive report on the global Pet Allergy Treatment Market. The report provides an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges, offering detailed insights into the market landscape.

Key Insights:

  • Pet Allergy Treatment Market Size (2024E): USD 2,671.20 million
  • Projected Market Value (2031F): USD 3,930.76 million
  • Global Market Growth Rate (CAGR 2024 to 2031):5.7%

Pet Allergy Treatment Market - Report Scope:

Pet allergies represent a significant health concern for both pets and their owners globally. The market for pet allergy treatment encompasses a range of therapeutic options aimed at managing allergic reactions caused by pets, such as cats and dogs. These treatments include medications, immunotherapy, allergen avoidance strategies, and emerging biologic therapies. The market caters to veterinary clinics, hospitals, pet care centers, and homecare settings, addressing a growing demand from pet owners seeking effective allergy management solutions.

Market Growth Drivers:

The global pet allergy treatment market is driven by several factors, including increasing pet ownership, rising awareness about pet allergies, and advancements in veterinary medicine. The growing prevalence of allergic conditions among pet owners and pets alike underscores the need for effective treatment options. Technological innovations in diagnostic tools and treatment modalities further enhance market growth, improving diagnostic accuracy and treatment efficacy. Moreover, the expanding pet insurance coverage and investments in pet healthcare infrastructure contribute to market expansion.

Market Restraints:

Despite promising growth prospects, the pet allergy treatment market faces challenges related to regulatory compliance, variability in treatment outcomes, and pet owner adherence to prescribed therapies. Regulatory frameworks governing veterinary pharmaceuticals and biologics impose compliance burdens on manufacturers and healthcare providers, influencing market dynamics and operational strategies. Additionally, the high cost of advanced treatments and limited reimbursement coverage in some regions hinder market penetration, particularly in emerging economies.

Market Opportunities:

The pet allergy treatment market presents significant growth opportunities driven by demographic trends, increasing pet humanization, and evolving consumer preferences for pet healthcare products and services. The integration of telemedicine and digital health solutions facilitates remote consultations and enhances pet owner access to veterinary care. Furthermore, collaborations between veterinary pharmaceutical companies, pet food manufacturers, and allergy specialists foster innovation in treatment protocols and allergen management strategies. Strategic investments in research and development, along with educational initiatives targeting pet owners and veterinary professionals, are essential to capitalize on emerging market opportunities.

Key Questions Answered in the Report:

  • What factors are driving the growth of the pet allergy treatment market globally?
  • Which treatment modalities and diagnostic tools are gaining traction among pet owners and veterinary professionals?
  • How are technological advancements reshaping the competitive landscape of the pet allergy treatment market?
  • Who are the key players contributing to the pet allergy treatment market, and what strategies are they employing to maintain market leadership?
  • What are the emerging trends and future prospects in the global pet allergy treatment market?

Competitive Intelligence and Business Strategy:

Leading players in the global pet allergy treatment market, including pharmaceutical companies, veterinary clinics, and biotechnology firms, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop novel therapies, diagnostic tests, and allergen management solutions, catering to diverse pet owner preferences and clinical needs. Collaborations with pet healthcare providers, regulatory agencies, and pet insurance companies facilitate market access and promote technology adoption. Moreover, emphasis on evidence-based practice, veterinary education, and pet owner engagement enhances treatment outcomes and supports sustainable market growth in the evolving landscape of pet allergy management.

Key Companies Profiled:

  • Zoetis Animal Healthcare
  • Merck and Co Inc.
  • Boehringer Ingelheim GmbH
  • Elanco Animal Health Incorporated
  • Bayer AG
  • Vetoquinol S.A.
  • Dechra Pharmaceuticals PLC
  • Virbac SA
  • IDEXX Laboratories, Inc.
  • Ceva Sante Animale
  • Kindred Biosciences, Inc.
  • Phirbo Animal Health
  • Norbrook Laboratories Limited
  • Vetiquinol SA
  • Neogen Corporation
  • PetIQ, Inc.
  • Huvepharma AD

Key Segments of Pet Allergy Treatment Industry Research

By Drug Class:

  • Antihistamines
  • Corticosteroids
  • Immunotherapy
  • Antibiotics

By Indication:

  • Allergic Dermatitis
  • Food Allergy
  • Fleabite Allergy
  • Contact Allergy

By Pet Type:

  • Dogs
  • Cats
  • Rodents & Rabbits

By Route of Administration:

  • Oral
  • Injectable
  • Topical

By Distribution Channel:

  • Veterinary Hospitals
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand-side Trends
  • 1.3. Supply-side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Value Added Insights

  • 4.1. Product Adoption Analysis
  • 4.2. Product USPs/Features Analysis, By Brands
  • 4.3. Regulatory Landscape, By Country
  • 4.4. Recent Product Approval/Launches
  • 4.5. Disease Epidemiology
  • 4.6. Porter's Analysis
  • 4.7. PESTLE Analysis
  • 4.8. Value Chain Analysis
  • 4.9. Unmet Needs

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global Healthcare Expenditure Outlook
    • 5.1.2. Global Pharmaceutical Market Outlook
    • 5.1.3. Global Animal Healthcare Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Rising Rate of Pet Adoption
    • 5.2.2. Increase in Research and Development
    • 5.2.3. Strategic Collaborations among players
    • 5.2.4. Cost of Product
    • 5.2.5. Business Expansions
    • 5.2.6. Frequency of Product Approval
    • 5.2.7. Pet Care Insurance
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. Global Market Demand (in Value or Size in US$ Million) Analysis 2019-2023 and Forecast, 2024-2031

  • 6.1. Historical Market Value (US$ Million) Analysis, 2019-2023
  • 6.2. Current and Future Market Size (US$ Million) Projections, 2024-2031
    • 6.2.1. Y-o-Y Growth Trend Analysis
    • 6.2.2. Absolute $ Opportunity Analysis
  • 6.3. Revenue Opportunity Scenario- Likely/Conservative/Optimistic

7. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Drug Class

  • 7.1. Introduction / Key Findings
  • 7.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2019-2023
  • 7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2024-2031
    • 7.3.1. Antihistamines
    • 7.3.2. Corticosteroids
    • 7.3.3. Immunotherapy
    • 7.3.4. Antibiotics
  • 7.4. Market Attractiveness Analysis By Drug Class

8. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Indication

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Million) Analysis By Indication, 2019-2023
  • 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2024-2031
    • 8.3.1. Allergic Dermatitis
    • 8.3.2. Food Allergy
    • 8.3.3. Fleabite Allergy
    • 8.3.4. Contact Allergy
  • 8.4. Market Attractiveness Analysis By Indication

9. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Pet Type

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Million) Analysis By Pet Type, 2019-2023
  • 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Pet Type, 2024-2031
    • 9.3.1. Dogs
    • 9.3.2. Cats
    • 9.3.3. Rodents and rabbits
  • 9.4. Market Attractiveness Analysis By Pet Type

10. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Route of Administration

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Million) Analysis By Route of Administration, 2019-2023
  • 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2024-2031
    • 10.3.1. Oral
    • 10.3.2. Injectable
    • 10.3.3. Topical
  • 10.4. Market Attractiveness Analysis By Route of Administration

11. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Distribution Channel

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2019-2023
  • 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2024-2031
    • 11.3.1. Veterinary Hospitals
    • 11.3.2. Retail Pharmacies
    • 11.3.3. Online Pharmacies
    • 11.3.4. Others
  • 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Market Analysis 2019-2023 and Forecast 2024-2031, by Region

  • 12.1. Introduction / Key Findings
  • 12.2. Historical Market Size (US$ Million) Analysis By Region, 2019-2023
  • 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2024-2031
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. South Asia
    • 12.3.5. East Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East and Africa
  • 12.4. Market Attractiveness Analysis By Region

13. North America Market Analysis 2019-2023 and Forecast 2024-2031

  • 13.1. Introduction / Key Findings
  • 13.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 13.3.1. By Country
      • 13.3.1.1. United States
      • 13.3.1.2. Canada
    • 13.3.2. By Drug Class
    • 13.3.3. By Indication
    • 13.3.4. By Pet Type
    • 13.3.5. By Route of Administration
    • 13.3.6. By Distribution Channel
  • 13.4. Market Attractiveness Analysis By Region
    • 13.4.1. By Country
    • 13.4.2. By Drug Class
    • 13.4.3. By Indication
    • 13.4.4. By Pet Type
    • 13.4.5. By Route of Administration
    • 13.4.6. By Distribution Channel
  • 13.5. Market trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. United States Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Drug Class
        • 13.8.1.2.2. By Indication
        • 13.8.1.2.3. By Pet Type
        • 13.8.1.2.4. By Route of Administration
        • 13.8.1.2.5. By Distribution Channel
    • 13.8.2. Canada Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Drug Class
        • 13.8.2.2.2. By Indication
        • 13.8.2.2.3. By Pet Type
        • 13.8.2.2.4. By Route of Administration
        • 13.8.2.2.5. By Distribution Channel

14. Latin America Market Analysis 2019-2023 and Forecast 2024-2031

  • 14.1. Introduction / Key Findings
  • 14.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 14.3.1. By Country
      • 14.3.1.1. Brazil
      • 14.3.1.2. Mexico
      • 14.3.1.3. Argentina
      • 14.3.1.4. Rest of Latin America
    • 14.3.2. By Drug Class
    • 14.3.3. By Indication
    • 14.3.4. By Pet Type
    • 14.3.5. By Route of Administration
    • 14.3.6. By Distribution Channel
  • 14.4. Market Attractiveness Analysis By Region
    • 14.4.1. By Country
    • 14.4.2. By Drug Class
    • 14.4.3. By Indication
    • 14.4.4. By Pet Type
    • 14.4.5. By Route of Administration
    • 14.4.6. By Distribution Channel
  • 14.5. Market trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Brazil Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Drug Class
        • 14.8.1.2.2. By Indication
        • 14.8.1.2.3. By Pet Type
        • 14.8.1.2.4. By Route of Administration
        • 14.8.1.2.5. By Distribution Channel
    • 14.8.2. Mexico Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Drug Class
        • 14.8.2.2.2. By Indication
        • 14.8.2.2.3. By Pet Type
        • 14.8.2.2.4. By Route of Administration
        • 14.8.2.2.5. By Distribution Channel
    • 14.8.3. Argentina Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Drug Class
        • 14.8.3.2.2. By Indication
        • 14.8.3.2.3. By Pet Type
        • 14.8.3.2.4. By Route of Administration
        • 14.8.3.2.5. By Distribution Channel

15. Europe Market Analysis 2019-2023 and Forecast 2024-2031

  • 15.1. Introduction / Key Findings
  • 15.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 15.3.1. By Country
      • 15.3.1.1. Germany
      • 15.3.1.2. France
      • 15.3.1.3. Spain
      • 15.3.1.4. Russia
      • 15.3.1.5. Italy
      • 15.3.1.6. BENELUX
      • 15.3.1.7. United Kingdom
      • 15.3.1.8. Rest of Europe
    • 15.3.2. By Drug Class
    • 15.3.3. By Indication
    • 15.3.4. By Pet Type
    • 15.3.5. By Route of Administration
    • 15.3.6. By Distribution Channel
  • 15.4. Market Attractiveness Analysis By Region
    • 15.4.1. By Country
    • 15.4.2. By Drug Class
    • 15.4.3. By Indication
    • 15.4.4. By Pet Type
    • 15.4.5. By Route of Administration
    • 15.4.6. By Distribution Channel
  • 15.5. Market trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. Germany Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Drug Class
        • 15.8.1.2.2. By Indication
        • 15.8.1.2.3. By Pet Type
        • 15.8.1.2.4. By Route of Administration
        • 15.8.1.2.5. By Distribution Channel
    • 15.8.2. France Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Drug Class
        • 15.8.2.2.2. By Indication
        • 15.8.2.2.3. By Pet Type
        • 15.8.2.2.4. By Route of Administration
        • 15.8.2.2.5. By Distribution Channel
    • 15.8.3. Spain Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Drug Class
        • 15.8.3.2.2. By Indication
        • 15.8.3.2.3. By Pet Type
        • 15.8.3.2.4. By Route of Administration
        • 15.8.3.2.5. By Distribution Channel
    • 15.8.4. Russia Market Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Drug Class
        • 15.8.4.2.2. By Indication
        • 15.8.4.2.3. By Pet Type
        • 15.8.4.2.4. By Route of Administration
        • 15.8.4.2.5. By Distribution Channel
    • 15.8.5. Italy Market Analysis
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.5.2.1. By Drug Class
        • 15.8.5.2.2. By Indication
        • 15.8.5.2.3. By Pet Type
        • 15.8.5.2.4. By Route of Administration
        • 15.8.5.2.5. By Distribution Channel
    • 15.8.6. BENELUX Market Analysis
      • 15.8.6.1. Introduction
      • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.6.2.1. By Drug Class
        • 15.8.6.2.2. By Indication
        • 15.8.6.2.3. By Pet Type
        • 15.8.6.2.4. By Route of Administration
        • 15.8.6.2.5. By Distribution Channel
    • 15.8.7. United Kingdom Market Analysis
      • 15.8.7.1. Introduction
      • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.7.2.1. By Drug Class
        • 15.8.7.2.2. By Indication
        • 15.8.7.2.3. By Pet Type
        • 15.8.7.2.4. By Route of Administration
        • 15.8.7.2.5. By Distribution Channel

16. East Asia Market Analysis 2019-2023 and Forecast 2024-2031

  • 16.1. Introduction / Key Findings
  • 16.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 16.3.1. By Country
      • 16.3.1.1. China
      • 16.3.1.2. Japan
      • 16.3.1.3. South Korea
    • 16.3.2. By Drug Class
    • 16.3.3. By Indication
    • 16.3.4. By Pet Type
    • 16.3.5. By Route of Administration
    • 16.3.6. By Distribution Channel
  • 16.4. Market Attractiveness Analysis By Region
    • 16.4.1. By Country
    • 16.4.2. By Drug Class
    • 16.4.3. By Indication
    • 16.4.4. By Pet Type
    • 16.4.5. By Route of Administration
    • 16.4.6. By Distribution Channel
  • 16.5. Market trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. China Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Drug Class
        • 16.8.1.2.2. By Indication
        • 16.8.1.2.3. By Pet Type
        • 16.8.1.2.4. By Route of Administration
        • 16.8.1.2.5. By Distribution Channel
    • 16.8.2. Japan Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Drug Class
        • 16.8.2.2.2. By Indication
        • 16.8.2.2.3. By Pet Type
        • 16.8.2.2.4. By Route of Administration
        • 16.8.2.2.5. By Distribution Channel
    • 16.8.3. South Korea Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Drug Class
        • 16.8.3.2.2. By Indication
        • 16.8.3.2.3. By Pet Type
        • 16.8.3.2.4. By Route of Administration
        • 16.8.3.2.5. By Distribution Channel

17. South Asia Market Analysis 2019-2023 and Forecast 2024-2031

  • 17.1. Introduction / Key Findings
  • 17.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 17.3.1. By Country
      • 17.3.1.1. India
      • 17.3.1.2. Indonesia
      • 17.3.1.3. Thailand
      • 17.3.1.4. Philippines
      • 17.3.1.5. Malaysia
      • 17.3.1.6. Vietnam
      • 17.3.1.7. Rest of South Asia
    • 17.3.2. By Drug Class
    • 17.3.3. By Indication
    • 17.3.4. By Pet Type
    • 17.3.5. By Route of Administration
    • 17.3.6. By Distribution Channel
  • 17.4. Market Attractiveness Analysis By Region
    • 17.4.1. By Country
    • 17.4.2. By Drug Class
    • 17.4.3. By Indication
    • 17.4.4. By Pet Type
    • 17.4.5. By Route of Administration
    • 17.4.6. By Distribution Channel
  • 17.5. Market trends
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. India Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Drug Class
        • 17.8.1.2.2. By Indication
        • 17.8.1.2.3. By Pet Type
        • 17.8.1.2.4. By Route of Administration
        • 17.8.1.2.5. By Distribution Channel
    • 17.8.2. Indonesia Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Drug Class
        • 17.8.2.2.2. By Indication
        • 17.8.2.2.3. By Pet Type
        • 17.8.2.2.4. By Route of Administration
        • 17.8.2.2.5. By Distribution Channel
    • 17.8.3. Thailand Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Drug Class
        • 17.8.3.2.2. By Indication
        • 17.8.3.2.3. By Pet Type
        • 17.8.3.2.4. By Route of Administration
        • 17.8.3.2.5. By Distribution Channel
    • 17.8.4. Philippines Market Analysis
      • 17.8.4.1. Introduction
      • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.4.2.1. By Drug Class
        • 17.8.4.2.2. By Indication
        • 17.8.4.2.3. By Pet Type
        • 17.8.4.2.4. By Route of Administration
        • 17.8.4.2.5. By Distribution Channel
    • 17.8.5. Malaysia Market Analysis
      • 17.8.5.1. Introduction
      • 17.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.5.2.1. By Drug Class
        • 17.8.5.2.2. By Indication
        • 17.8.5.2.3. By Pet Type
        • 17.8.5.2.4. By Route of Administration
        • 17.8.5.2.5. By Distribution Channel
    • 17.8.6. Vietnam Market Analysis
      • 17.8.6.1. Introduction
      • 17.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.6.2.1. By Drug Class
        • 17.8.6.2.2. By Indication
        • 17.8.6.2.3. By Pet Type
        • 17.8.6.2.4. By Route of Administration
        • 17.8.6.2.5. By Distribution Channel

18. Oceania Market Analysis 2019-2023 and Forecast 2024-2031

  • 18.1. Introduction / Key Findings
  • 18.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 18.3.1. By Country
      • 18.3.1.1. Australia
      • 18.3.1.2. New Zealand
    • 18.3.2. By Drug Class
    • 18.3.3. By Indication
    • 18.3.4. By Pet Type
    • 18.3.5. By Route of Administration
    • 18.3.6. By Distribution Channel
  • 18.4. Market Attractiveness Analysis By Region
    • 18.4.1. By Country
    • 18.4.2. By Drug Class
    • 18.4.3. By Indication
    • 18.4.4. By Pet Type
    • 18.4.5. By Route of Administration
    • 18.4.6. By Distribution Channel
  • 18.5. Market trends
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. Australia Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.1.2.1. By Drug Class
        • 18.8.1.2.2. By Indication
        • 18.8.1.2.3. By Pet Type
        • 18.8.1.2.4. By Route of Administration
        • 18.8.1.2.5. By Distribution Channel
    • 18.8.2. New Zealand Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.2.2.1. By Drug Class
        • 18.8.2.2.2. By Indication
        • 18.8.2.2.3. By Pet Type
        • 18.8.2.2.4. By Route of Administration
        • 18.8.2.2.5. By Distribution Channel

19. Middle East and Africa Market Analysis 2019-2023 and Forecast 2024-2031

  • 19.1. Introduction / Key Findings
  • 19.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 19.3.1. By Country
      • 19.3.1.1. GCC Countries
      • 19.3.1.2. Turkey
      • 19.3.1.3. Egypt
      • 19.3.1.4. Israel
      • 19.3.1.5. South Africa
      • 19.3.1.6. Northern Africa
      • 19.3.1.7. Rest of Middle East and Africa
    • 19.3.2. By Drug Class
    • 19.3.3. By Indication
    • 19.3.4. By Pet Type
    • 19.3.5. By Route of Administration
    • 19.3.6. By Distribution Channel
  • 19.4. Market Attractiveness Analysis By Region
    • 19.4.1. By Country
    • 19.4.2. By Drug Class
    • 19.4.3. By Indication
    • 19.4.4. By Pet Type
    • 19.4.5. By Route of Administration
    • 19.4.6. By Distribution Channel
  • 19.5. Market trends
  • 19.6. Key Market Participants - Intensity Mapping
  • 19.7. Drivers and Restraints - Impact Analysis
  • 19.8. Country Level Analysis & Forecast
    • 19.8.1. GCC Countries Market Analysis
      • 19.8.1.1. Introduction
      • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.1.2.1. By Drug Class
        • 19.8.1.2.2. By Indication
        • 19.8.1.2.3. By Pet Type
        • 19.8.1.2.4. By Route of Administration
        • 19.8.1.2.5. By Distribution Channel
    • 19.8.2. Turkey Market Analysis
      • 19.8.2.1. Introduction
      • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.2.2.1. By Drug Class
        • 19.8.2.2.2. By Indication
        • 19.8.2.2.3. By Pet Type
        • 19.8.2.2.4. By Route of Administration
        • 19.8.2.2.5. By Distribution Channel
    • 19.8.3. Egypt Market Analysis
      • 19.8.3.1. Introduction
      • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.3.2.1. By Drug Class
        • 19.8.3.2.2. By Indication
        • 19.8.3.2.3. By Pet Type
        • 19.8.3.2.4. By Route of Administration
        • 19.8.3.2.5. By Distribution Channel
    • 19.8.4. Israel Market Analysis
      • 19.8.4.1. Introduction
      • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.4.2.1. By Drug Class
        • 19.8.4.2.2. By Indication
        • 19.8.4.2.3. By Pet Type
        • 19.8.4.2.4. By Route of Administration
        • 19.8.4.2.5. By Distribution Channel
    • 19.8.5. South Africa Market Analysis
      • 19.8.5.1. Introduction
      • 19.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.5.2.1. By Drug Class
        • 19.8.5.2.2. By Indication
        • 19.8.5.2.3. By Pet Type
        • 19.8.5.2.4. By Route of Administration
        • 19.8.5.2.5. By Distribution Channel
    • 19.8.6. Northern Africa Market Analysis
      • 19.8.6.1. Introduction
      • 19.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.6.2.1. By Drug Class
        • 19.8.6.2.2. By Indication
        • 19.8.6.2.3. By Pet Type
        • 19.8.6.2.4. By Route of Administration
        • 19.8.6.2.5. By Distribution Channel

20. Market Structure Analysis

  • 20.1. Market Analysis by Tier of Companies
  • 20.2. Market Share Analysis of Top Players (%)
  • 20.3. Market Presence Analysis
    • 20.3.1. Regional Footprint of Players
    • 20.3.2. Product Footprint of Players
    • 20.3.3. Channel Footprint of Players

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Key Development Analysis
  • 21.3. Branding and Promotional Strategies, By Key Players
  • 21.4. Competition Deep Dive
    • 21.4.1. Zoetis Animal Healthcare
      • 21.4.1.1. Overview
      • 21.4.1.2. Product Portfolio
      • 21.4.1.3. Key Financials
      • 21.4.1.4. Sales Footprint
      • 21.4.1.5. SWOT Analysis
      • 21.4.1.6. Strategy Overview
        • 21.4.1.6.1. Marketing Strategies
        • 21.4.1.6.2. Channel Strategies
        • 21.4.1.6.3. Product Strategies
    • 21.4.2. Merck and Co.Inc. (US)
      • 21.4.2.1. Overview
      • 21.4.2.2. Product Portfolio
      • 21.4.2.3. Key Financials
      • 21.4.2.4. Sales Footprint
      • 21.4.2.5. SWOT Analysis
      • 21.4.2.6. Strategy Overview
        • 21.4.2.6.1. Marketing Strategies
        • 21.4.2.6.2. Channel Strategies
        • 21.4.2.6.3. Product Strategies
    • 21.4.3. Boehringer Ingelheim GmbH
      • 21.4.3.1. Overview
      • 21.4.3.2. Product Portfolio
      • 21.4.3.3. Key Financials
      • 21.4.3.4. Sales Footprint
      • 21.4.3.5. SWOT Analysis
      • 21.4.3.6. Strategy Overview
        • 21.4.3.6.1. Marketing Strategies
        • 21.4.3.6.2. Channel Strategies
        • 21.4.3.6.3. Product Strategies
    • 21.4.4. Elanco Animal Health Incorporated
      • 21.4.4.1. Overview
      • 21.4.4.2. Product Portfolio
      • 21.4.4.3. Key Financials
      • 21.4.4.4. Sales Footprint
      • 21.4.4.5. SWOT Analysis
      • 21.4.4.6. Strategy Overview
        • 21.4.4.6.1. Marketing Strategies
        • 21.4.4.6.2. Channel Strategies
        • 21.4.4.6.3. Product Strategies
    • 21.4.5. Bayer AG
      • 21.4.5.1. Overview
      • 21.4.5.2. Product Portfolio
      • 21.4.5.3. Key Financials
      • 21.4.5.4. Sales Footprint
      • 21.4.5.5. SWOT Analysis
      • 21.4.5.6. Strategy Overview
        • 21.4.5.6.1. Marketing Strategies
        • 21.4.5.6.2. Channel Strategies
        • 21.4.5.6.3. Product Strategies
    • 21.4.6. Vetoquinol S.A.
      • 21.4.6.1. Overview
      • 21.4.6.2. Product Portfolio
      • 21.4.6.3. Key Financials
      • 21.4.6.4. Sales Footprint
      • 21.4.6.5. SWOT Analysis
      • 21.4.6.6. Strategy Overview
        • 21.4.6.6.1. Marketing Strategies
        • 21.4.6.6.2. Channel Strategies
        • 21.4.6.6.3. Product Strategies
    • 21.4.7. Dechra Pharmaceuticals PLC
      • 21.4.7.1. Overview
      • 21.4.7.2. Product Portfolio
      • 21.4.7.3. Key Financials
      • 21.4.7.4. Sales Footprint
      • 21.4.7.5. SWOT Analysis
      • 21.4.7.6. Strategy Overview
        • 21.4.7.6.1. Marketing Strategies
        • 21.4.7.6.2. Channel Strategies
        • 21.4.7.6.3. Product Strategies
    • 21.4.8. Virbac SA
      • 21.4.8.1. Overview
      • 21.4.8.2. Product Portfolio
      • 21.4.8.3. Key Financials
      • 21.4.8.4. Sales Footprint
      • 21.4.8.5. SWOT Analysis
      • 21.4.8.6. Strategy Overview
        • 21.4.8.6.1. Marketing Strategies
        • 21.4.8.6.2. Channel Strategies
        • 21.4.8.6.3. Product Strategies
    • 21.4.9. IDEXX Laboratories, Inc.
      • 21.4.9.1. Overview
      • 21.4.9.2. Product Portfolio
      • 21.4.9.3. Key Financials
      • 21.4.9.4. Sales Footprint
      • 21.4.9.5. SWOT Analysis
      • 21.4.9.6. Strategy Overview
        • 21.4.9.6.1. Marketing Strategies
        • 21.4.9.6.2. Channel Strategies
        • 21.4.9.6.3. Product Strategies
    • 21.4.10. Ceva Sante Animale
      • 21.4.10.1. Overview
      • 21.4.10.2. Product Portfolio
      • 21.4.10.3. Key Financials
      • 21.4.10.4. Sales Footprint
      • 21.4.10.5. SWOT Analysis
      • 21.4.10.6. Strategy Overview
        • 21.4.10.6.1. Marketing Strategies
        • 21.4.10.6.2. Channel Strategies
        • 21.4.10.6.3. Product Strategies
    • 21.4.11. Kindred Biosciences, Inc.
      • 21.4.11.1. Overview
      • 21.4.11.2. Product Portfolio
      • 21.4.11.3. Key Financials
      • 21.4.11.4. Sales Footprint
      • 21.4.11.5. SWOT Analysis
      • 21.4.11.6. Strategy Overview
        • 21.4.11.6.1. Marketing Strategies
        • 21.4.11.6.2. Channel Strategies
        • 21.4.11.6.3. Product Strategies
    • 21.4.12. Phirbo Animal Health
      • 21.4.12.1. Overview
      • 21.4.12.2. Product Portfolio
      • 21.4.12.3. Key Financials
      • 21.4.12.4. Sales Footprint
      • 21.4.12.5. SWOT Analysis
      • 21.4.12.6. Strategy Overview
        • 21.4.12.6.1. Marketing Strategies
        • 21.4.12.6.2. Channel Strategies
        • 21.4.12.6.3. Product Strategies
    • 21.4.13. Norbrook Laboratories Limited
      • 21.4.13.1. Overview
      • 21.4.13.2. Product Portfolio
      • 21.4.13.3. Key Financials
      • 21.4.13.4. Sales Footprint
      • 21.4.13.5. SWOT Analysis
      • 21.4.13.6. Strategy Overview
        • 21.4.13.6.1. Marketing Strategies
        • 21.4.13.6.2. Channel Strategies
        • 21.4.13.6.3. Product Strategies
    • 21.4.14. Vetiquinol SA
      • 21.4.14.1. Overview
      • 21.4.14.2. Product Portfolio
      • 21.4.14.3. Key Financials
      • 21.4.14.4. Sales Footprint
      • 21.4.14.5. SWOT Analysis
      • 21.4.14.6. Strategy Overview
        • 21.4.14.6.1. Marketing Strategies
        • 21.4.14.6.2. Channel Strategies
        • 21.4.14.6.3. Product Strategies
    • 21.4.15. Neogen Corporation
      • 21.4.15.1. Overview
      • 21.4.15.2. Product Portfolio
      • 21.4.15.3. Key Financials
      • 21.4.15.4. Sales Footprint
      • 21.4.15.5. SWOT Analysis
      • 21.4.15.6. Strategy Overview
        • 21.4.15.6.1. Marketing Strategies
        • 21.4.15.6.2. Channel Strategies
        • 21.4.15.6.3. Product Strategies
    • 21.4.16. PetIQ, Inc.
      • 21.4.16.1. Overview
      • 21.4.16.2. Product Portfolio
      • 21.4.16.3. Key Financials
      • 21.4.16.4. Sales Footprint
      • 21.4.16.5. SWOT Analysis
      • 21.4.16.6. Strategy Overview
        • 21.4.16.6.1. Marketing Strategies
        • 21.4.16.6.2. Channel Strategies
        • 21.4.16.6.3. Product Strategies
    • 21.4.17. Huvepharma AD
      • 21.4.17.1. Overview
      • 21.4.17.2. Product Portfolio
      • 21.4.17.3. Key Financials
      • 21.4.17.4. Sales Footprint
      • 21.4.17.5. SWOT Analysis
      • 21.4.17.6. Strategy Overview
        • 21.4.17.6.1. Marketing Strategies
        • 21.4.17.6.2. Channel Strategies
        • 21.4.17.6.3. Product Strategies
    • 21.4.18. Chanelle Pharma Group Limited
      • 21.4.18.1. Overview
      • 21.4.18.2. Product Portfolio
      • 21.4.18.3. Key Financials
      • 21.4.18.4. Sales Footprint
      • 21.4.18.5. SWOT Analysis
      • 21.4.18.6. Strategy Overview
        • 21.4.18.6.1. Marketing Strategies
        • 21.4.18.6.2. Channel Strategies
        • 21.4.18.6.3. Product Strategies
    • 21.4.19. Kepro
      • 21.4.19.1. Overview
      • 21.4.19.2. Product Portfolio
      • 21.4.19.3. Key Financials
      • 21.4.19.4. Sales Footprint
      • 21.4.19.5. SWOT Analysis
      • 21.4.19.6. Strategy Overview
        • 21.4.19.6.1. Marketing Strategies
        • 21.4.19.6.2. Channel Strategies
        • 21.4.19.6.3. Product Strategies
    • 21.4.20. Biogenesis Bago
      • 21.4.20.1. Overview
      • 21.4.20.2. Product Portfolio
      • 21.4.20.3. Key Financials
      • 21.4.20.4. Sales Footprint
      • 21.4.20.5. SWOT Analysis
      • 21.4.20.6. Strategy Overview
        • 21.4.20.6.1. Marketing Strategies
        • 21.4.20.6.2. Channel Strategies
        • 21.4.20.6.3. Product Strategies

22. Assumptions and Acronyms Used

23. Research Methodology